Plasminogen activator inhibitor-1 inhibitors and methods of use thereof
US-9718760-B2 · Aug 1, 2017 · US
Plasminogen activator inhibitor-1 (PAI-1) inhibitor and method of use
US11426368B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11426368-B2 |
| Application number | US-201816631066-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 27, 2018 |
| Priority date | Jul 27, 2017 |
| Publication date | Aug 30, 2022 |
| Grant date | Aug 30, 2022 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Provided herein are plasminogen activator-1 (PAI-1) inhibitor compounds and uses thereof in the treatment of any disease or disorder associated with elevated PAI-1. The disclosure includes, but is not limited to, the use of such compounds to prevent or reduce thrombosis and fibrosis, to promote thrombolysis, and to modulate lipid metabolism and treat diseases or disorders associated with elevated PAI-1, cholesterol, or lipid levels.
First claim
Opening claim text (preview).
What is claimed: 1. A compound having a structure of: or a pharmaceutically acceptable salt thereof.
Assignees
Inventors
Classifications
- C07C243/26Primary
with acylating carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms · CPC title
- A61K31/137Primary
Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone} · CPC title
Immunosuppressants, e.g. drugs for graft rejection · CPC title
Drugs for skeletal disorders · CPC title
of the kidneys · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11426368B2 cover?
- Provided herein are plasminogen activator-1 (PAI-1) inhibitor compounds and uses thereof in the treatment of any disease or disorder associated with elevated PAI-1. The disclosure includes, but is not limited to, the use of such compounds to prevent or reduce thrombosis and fibrosis, to promote thrombolysis, and to modulate lipid metabolism and treat diseases or disorders associated with elevat…
- Who is the assignee on this patent?
- Univ Michigan Regents, Eastern Michigan Univ
- What technology area does this patent fall under?
- Primary CPC classification C07C243/26. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Aug 30 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 3 related publications on this page (citations in our corpus or others sharing the same primary CPC).